Pfizer's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in ...

Moderna MRNA is expected to report first-quarter 2025 earnings on May 1, before the opening bell. The company’s earnings beat ...

Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Moderna faces challenges with respiratory vaccine sales and strong competition. Click here to read an analysis of MRNA stock ...

In 2023 – the first year that Arexvy and Abrysvo were approved – the ACIP's recommendation was that they could be used in all adults over the age of 60 if deemed appropriate by their doctor ...

Stocks ended in the red for the holiday-shortened week, as developments over tariffs and tensions between U.S. President Donald Trump and Federal Reserve chair Jerome Powell continued to dominate ...

For comparison, Pfizer reported yesterday that Abrysvo made full-year sales of $890 million, which - while respectable - were well below its competitor. However, it brought in $515 million in the ...

Brazil's Vice President Geraldo Alckmin stayed at home Monday after being diagnosed with Covid-19, Agencia Brasil reported. Alckin is also Minister of Development, Industry, Trade, and Services.

"Who We Are." ETF.com. "SPY – SPDR S&P 500 ETF Trust." Pfizer. "U.S. FDA Approves Pfizer's RSV Vaccine ABRYSVO for Adults Aged 18 to 59 at Increased Risk for Disease." Pfizer. "U.S. FDA Approves ...